Lantern Pharma’s ongoing HARMONIC™ clinical trial has yielded promising early results. The trial examines the efficacy of LP-300, a novel drug candidate, combined with chemotherapy in non-smokers with advanced non-small cell lung cancer (NSCLC).
HARMONIC™’s initial patient cohort showed encouraging safety and efficacy outcomes. LP-300 did not produce any unexpected adverse events, with side effects mainly attributable to the chemotherapy regimen. In addition, preliminary findings indicated a high clinical benefit rate, suggesting potential therapeutic potential for LP-300.
Lantern’s AI platform, RADR®, played a crucial role in developing LP-300, facilitating target validation and patient population identification. The trial’s expansion phase is underway, enrolling patients to assess progression-free and overall survival.
For NSCLC patients who have progressed on TKI therapy, treatment options are limited, often leaving them with poor outcomes when receiving standard chemotherapy. The promising results from the HARMONIC™ trial suggest that LP-300 may offer an innovative treatment approach for this population.
Lantern’s ongoing research aims to address the critical need for novel therapies in non-smokers with NSCLC who have failed TKI treatments. The HARMONIC™ trial provides evidence of both the safety and potential efficacy of LP-300, offering hope for improved outcomes in this patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
